Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Hansa Biopharma AB Sweden

Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).and will also be made available online after the call.

To participate in the telephone conference, please use the dial-in details provided below:
Participant Dial In (Toll Free): 1-833-821-3542
Participant International Dial In: 1-412-652-1248
*Please ask to be joined into the Hansa Biopharma call

Join the webcast here: Webcast | Hansa Biopharma Fourth Quarter 2025 Earnings

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
[e-mail]

Kerstin Falck, VP Global Corporate Affairs
[e-mail]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results,c4305662

The following files are available for download:

https://mb.cision.com/Main/1219/4305662/3928047.pdf

HNSA - Q4 2025 ENG Final

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-302684740.html